Artificial placenta for extreme prematurity
A fluid-filled sterile chamber plus umbilical oxygenator circuit that continues fetal development outside the uterus from roughly 22 weeks.
State of the art
CHOP EXTEND pumpless umbilical-access system supported 105-118-day gestation lambs with evidence of protected lung, brain, gut and kidney development (FDA Pediatric Advisory Committee, September 2023); reviews in 2026 still report no human trials conducted.
- Miniaturization - the lamb model weighs 1-3 kg while a 23-week human fetus is about 500 g, with shorter umbilical cannulation distances
- Umbilical vessel vasospasm and thrombosis during cannulation and over weeks of support
- Infection control in a continuously exchanged sterile fluid environment
- No agreed proof-of-concept endpoint or animal model that maps onto human neonatal outcomes
Who’s working on it
- Vitara Biomedical ↗Startup
Philadelphia company founded in 2019 to commercialise the CHOP EXTEND fluid-filled neonatal support system; filed a $50M Series B offering in October 2024 and remains pre-clearance
- Alan FlakeResearcherChildren's Hospital of Philadelphia
Co-inventor of EXTEND; his group kept 105-118-day-gestation lambs alive on pumpless umbilical access with protected organ development (2017 onward)
- Marcus DaveyResearcherVitara Biomedical
Co-inventor of the EXTEND circuit and leads its preclinical research program
- George MychaliskaResearcherUniversity of Michigan C.S. Mott Children's Hospital
Runs the NIH-funded artificial placenta program in Robert Bartlett's ECMO lab, supporting premature lambs for up to several weeks with lung and brain protection
- Perinatal Life Support (PLS) consortiumProgram
EU Horizon 2020 project (grant 863087) coordinated from Eindhoven University of Technology since 2019, building a liquid-based artificial womb prototype plus simulation-based clinical protocols
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| engineering | Device miniaturization and cannulation hardware qualified in a sub-kilogram animal model | $$ $10M – $100M |
| policy | Trial design and consent framework for a first-in-human study at the edge of viability, with long-term neurodevelopmental follow-up | $ < $10M |